Semagard is a semaglutide generic that has been tested in phase III clinical trials and
has been proven to be bioequivalent and as effective as the semaglutide originator
product.1-3 Semaglutide is a glucagon-like peptide 1 (GLP-1) receptor agonist, which
means it mimics the GLP-1 hormone that occurs naturally in the body. It is used to
manage diabetes through its effect on other hormones such as insulin and glucagon.4
Generic is a medication created to be the same as a brand-name drug in safety, dosage, strength, quality and performance. They contain identical active ingredients but are typically more affordable as they enter
the market after the patent on the original product has expired.
Phase III trials are large-scale, final-stage clinical trials in human subjects that evaluate the safety and efficacy of a new treatment compared to standard treatment.
Bioequivalent means that it contains the same active ingredient that delivers the same amount of medication to the bloodstream at the same rate and extent as the originator making it therapeutically equivalent.
Peptide is a short chain of amino acids that function as signalling molecules in the body, regulating processes such as metabolism, immune function and inflammation.
Agonist is a substance that binds to a cell receptor and activates it, thereby triggering a biological response.
WHAT IS
SEMAGARD
INDICATED FOR?
Semagard is indicated:3
• For the treatment of adults with poorly controlled
type 2 diabetes mellitus as an ‘add-on’ to diet and exercise
o Either as a single treatment on its own when
metformin is contraindicated or not tolerated
o Or as a combination treatment with oral anti-diabetic
medications (OADs) e.g. metformin or basal insulin
± metformin or pre-mix insulin
WHO CAN USE SEMAGARD?
Semagard can only be used by adults (≥ 18 years old) and people
living with type 2 diabetes mellitus.3 No dosage adjustment is
necessary in the elderly (≥ 65 years) and people with poor kidney
or liver function, however they should be monitored carefully.3
People with type 1 diabetes mellitus
People with a personal or family history of thyroid carcinoma
Patients with Multiple Endocrine Neoplasia Syndrome type 2 (MEN 2)
Pregnant or breastfeeding women
Uncontrolled diabetic retinopathy (visual problems associated with poorly controlled diabetes)